AVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market Opportunity

VALENCIA, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the U.S. commercial launch of Cohealyx™, a collagen-based dermal matrix branded by AVITA Medical and co-developed with Regenity Biosciences. Cohealyx is designed to facilitate cellular migration and revascularization, thereby providing an ideal wound bed for definitive closure. In pre-clinical and initial clinical utilization, an integrated wound bed was seen as early as 7 days.

Read more at globenewswire.com